Randomized trial evaluates safety and efficacy of LMY-920 CAR-T cells in patients with refractory non-Hodgkin lymphoma, suggesting a new treatment approach.
Key Points
To evaluate the safety and efficacy of LMY-920 CAR-T cells in refractory B cell non-Hodgkin lymphoma patients.
Patients with refractory B cell NHL are treated (NCT05312801).
CAR-T cells are manufactured using a novel transposon system. Patients receive a lymphodepletion regimen with fludarabine and cyclophosphamide.
LMY-920 is administered intravenously with a 3+3 dose escalation design from 1-8 x 10^6 BAFF-CAR-T cells/kg.
Five patients treated with initial doses of 1-2 x 10^6 BAFF-CAR-T cells/kg.
Responses included 2 complete responses, one partial response, and stable disease, with no dose-limiting toxicities reported.
All patients experienced grade 3 or higher hematologic toxicity that recovered by day 28.